Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
About the Musella Foundation
Dr. Henry Friedman and Dr. Linda Liau
reviewed and approved the contents of this guide.
https://static1.squarespace.com/static/5c0062f3e17ba398a2a5aaf4/t/62db39ffb1b73a149a5e8da6/1658534455242/BrainTumorGuidev12web.pdf
Matthew Hassan, M.S., PMP, CSM, SA
'Let's save my daughter's life rather than just taking her home to die,' says devoted Willington mum
12:45, 21 SEP 2023
Short Interest 48,940,579 shares - source: FINRA
Short Interest Ratio 31.61 Days to Cover
US:NWBO Short Shares Availability
3 minutes ago 2023-09-21 15:59:15.784 400,000
Short Borrow Fee Rates
2023-09-21 27.29 27.29 37.41 37.41
https://fintel.io/ss/us/nwbo
China
On MHRA approval ................. beyond UK patients ......
DCVax-L for GBM
15,000 annual gbm deaths in Europe (link previously posted)
2,000 annual gbm deaths in Australia (link previously posted)
9,000 annual gbm deaths in USA (link previously posted)
right now they can scale up to 1,000 patients a month (link previously posted)
About 200,000 people die each year from a glioblastoma in the world,
including nearly 15,000 in Europe
and 9,000 in the United States.
https://www.gliocure.com/en/patients/glioblastoma/#:~:text=About%20200%2C000%20people%20die%20each,9%2C000%20in%20the%20United%20States.
After MHRA DCVax-L approval - and given 15,000 gbm deaths EACH YEAR in Europe - the demand for
DCVax-L (I think) will be overwhelming.
Norway has a problem
MHRA Corporate Plan: What are the MHRA’s strategic objectives for medicines and medical devices 2023 to 2026?
European Union, United Kingdom September 15 2023
The priority regulatory pathways that the MHRA have indicated they will support are:
* Vaccines and immunotherapies
* Biotherapeutics, cells and gene therapies
* Diagnostics and genomics
* Data science
* Artificial intelligence and software as a medical device
https://www.lexology.com/library/detail.aspx?g=0d93c471-a053-44da-8ff0-cf818a56cfec
Luke
September 14, 2023
Al Musella and Linda Liau ....
from
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172781281
Our Prior Phase I/II DCVax-L Trials for GBM
We, together with our collaborator, Dr. Linda Liau, conducted two prior Phase I/II clinical trials at UCLA with DCVax-L for GBM brain cancer.
Co Down women's hiking group taking on Luke's Loop to fund life-saving vaccine
In March of this year, Luke received the devastating diagnosis of a stage 4 glioblastoma, following the discovery of a brain tumour, at the age of just 35
30 AUG 2023
Fight to save dying Gulf War veteran who 'dedicated life to country'
He might only have between eight to 18 months to live
05:42, 21 AUG 2023
Add 30% .........
After calculating a market cap based on annual DCVax sales
Add (an additional) 30% of that market cap back to your original market cap
You have to do this to account for a valuation for Direct
The 30% is arbitrary - it could be higher - but probably not lower
If you don't see this follow the NCVR chart for the last 6 months
its market cap went from almost 6 billion down to 2 billion once the
market realized some of its (Direct (metaphor)) wasn't going to materialize
We *already* know that Direct works ...........
roughly 15 million shares sold short on interactive brokers.
Thanks
average duration is 141 days which would be about April 18 when the share price was .55
ThanksThanks
The margin requirement is 387%.
ThanksThanksThanks
average short position is now underwater.
ThanksThanksThanksThanks
I think this says -
MHRA may approve (x) based on approval by
European Commission (European Medicines Agency ?)
My question is - is there a _CURRENT_ path by which an approval by MHRA can be used be EMA
to approve (x)
GBM - Tumour location - see left hemishere patient outcomes
Norway - about 450 people - GBM - mostly wildtype
graphs
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions
February 2, 2023
gbm Norway
rGBM
[[ this refers to ALL rGBM - which is not the primary subject of this paper ]]
Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults
2023 Aug; 15(15): 3901.
Today's survival with recurrent GBM
13% = 13% = 13% which is more than double the 5% that exists today .....
Of course, giving DCVax to a population of 100,000 may result in a higher or
much higher % ALIVE than the 13% experienced in the P3 trial
As you know, the recurrence patients survival was off the charts ....
Co Down women's hiking group taking on Luke's Loop to fund life-saving vaccine
In March of this year, Luke received the devastating diagnosis of a stage 4 glioblastoma, following the discovery of a brain tumour, at the age of just 35
14:31, 29 AUG 2023UPDATED15:12, 30 AUG 2023
...
VIDEO CONFERENCE “THE STORY OF TED”
29 September 2022 0 By ROBERTO PUGLIESE (ADMIN)
Ted's Story
My name is Ted Taylor
Significant regulation overhaul sees clinical trial approvals streamlined
29 March 2023
MHRA